Profil
Chang Rung Chen was the founder of Processa Pharmaceuticals, Inc. (founded in 2011) where he held the title of Senior Director-Translational Science until 2022.
He also held the position of Director-Bimolecular Discovery at ArQule, Inc. and Director-Translational Research & Pharmacology at Questcor Pharmaceuticals, Inc. from 2015 to 2016.
Dr. Chen received his graduate and doctorate degrees from New York University and his undergraduate degree from Tunghai University.
Anciens postes connus de Chang Rung Chen
Sociétés | Poste | Fin |
---|---|---|
PROCESSA PHARMACEUTICALS, INC. | Founder | 01/11/2022 |
QUESTCOR PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2016 |
ARQULE, INC. | Corporate Officer/Principal | - |
Formation de Chang Rung Chen
New York University | Doctorate Degree |
Tunghai University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
PROCESSA PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
ArQule, Inc.
ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Questcor Pharmaceuticals, Inc.
Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |